Entera Bio (ENTX) Stock Overview
A clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ENTX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Entera Bio Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.17 |
| 52 Week High | US$3.22 |
| 52 Week Low | US$0.91 |
| Beta | 1.54 |
| 1 Month Change | -21.48% |
| 3 Month Change | -26.88% |
| 1 Year Change | -30.77% |
| 3 Year Change | 30.00% |
| 5 Year Change | -64.55% |
| Change since IPO | -81.37% |
Recent News & Updates
Recent updates
Is Entera Bio (NASDAQ:ENTX) In A Good Position To Invest In Growth?
Jan 31
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation
Jul 17We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
Dec 07We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
Jul 12Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation
Mar 23We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
May 31Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?
Feb 15Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?
Oct 13Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M
Aug 11We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully
Jun 10Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth
Jan 21We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow
Oct 06Shareholder Returns
| ENTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.1% | 0.6% | 3.0% |
| 1Y | -30.8% | 41.7% | 25.7% |
Return vs Industry: ENTX underperformed the US Biotechs industry which returned 45% over the past year.
Return vs Market: ENTX underperformed the US Market which returned 32.8% over the past year.
Price Volatility
| ENTX volatility | |
|---|---|
| ENTX Average Weekly Movement | 16.5% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: ENTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ENTX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 21 | Miranda Toledano | enterabio.com |
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption.
Entera Bio Ltd. Fundamentals Summary
| ENTX fundamental statistics | |
|---|---|
| Market cap | US$55.01m |
| Earnings (TTM) | -US$11.44m |
| Revenue (TTM) | US$42.00k |
Is ENTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENTX income statement (TTM) | |
|---|---|
| Revenue | US$42.00k |
| Cost of Revenue | US$42.00k |
| Gross Profit | US$0 |
| Other Expenses | US$11.44m |
| Earnings | -US$11.44m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 0% |
| Net Profit Margin | -27,235.71% |
| Debt/Equity Ratio | 0% |
How did ENTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/09 07:48 |
| End of Day Share Price | 2026/04/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Entera Bio Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| null null | CG Capital |
| Raghuram Selvaraju | H.C. Wainwright & Co. |